QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:STML

Stemline Therapeutics - STML Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$11.83
$11.83
50-Day Range
$11.83
$11.83
52-Week Range
$3.21
$18.22
Volume
1,084 shs
Average Volume
1.52 million shs
Market Capitalization
$621.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
STML stock logo

About Stemline Therapeutics (NASDAQ:STML) Stock

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.

Receive STML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STML Stock News Headlines

Trade These 7 Stocks Under $10 for Huge Profits
Stemline Therapeutics acquired by Menarini Group
MVIS, STML, PBI and RRD among midday movers
See More Headlines

Receive STML Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STML Company Calendar

Last Earnings
11/07/2019
Today
8/11/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STML
Fax
N/A
Employees
92
Year Founded
N/A

Profitability

Net Income
$-76,820,000.00
Net Margins
-150.30%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$43.22 million
Book Value
$3.26 per share

Miscellaneous

Free Float
N/A
Market Cap
$621.21 million
Optionable
Optionable
Beta
1.78

Key Executives

  • Dr. Ivan Bergstein (Age 53)
    Founder, Pres, CEO & Chairman
  • Mr. David G. Gionco (Age 59)
    VP of Fin. & Chief Accounting Officer
  • Mr. Kenneth Hoberman (Age 54)
    COO & Corp. Sec.
  • Mr. Robert Francomano
    Sr. VP & Global Head of Commercial
  • Mr. John A. Salvagno
    Sr. VP of Quality & Operations













STML Stock - Frequently Asked Questions

How were Stemline Therapeutics' earnings last quarter?

Stemline Therapeutics Inc (NASDAQ:STML) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.08. The biopharmaceutical company earned $13.33 million during the quarter, compared to analyst estimates of $13.40 million. Stemline Therapeutics had a negative net margin of 150.30% and a negative trailing twelve-month return on equity of 48.14%.

What other stocks do shareholders of Stemline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Viking Therapeutics (VKTX), ZIOPHARM Oncology (ZIOP), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Bausch Health Companies (BHC), FireEye (FEYE), NVIDIA (NVDA) and Sorrento Therapeutics (SRNE).

What is Stemline Therapeutics' stock symbol?

Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."

What is Stemline Therapeutics' stock price today?

One share of STML stock can currently be purchased for approximately $11.83.

How much money does Stemline Therapeutics make?

Stemline Therapeutics (NASDAQ:STML) has a market capitalization of $621.21 million and generates $43.22 million in revenue each year. The biopharmaceutical company earns $-76,820,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How can I contact Stemline Therapeutics?

Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The official website for the company is www.stemline.com. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at investorrelations@stemline.com.

This page (NASDAQ:STML) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.